The Wnt signaling networks in higher-grade meningiomas: from molecular pathogenesis to therapeutic innovation.
- 1Department of Neurosurgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 320, Helsinki, FI- 00029, Finland. [email protected].
- 2Department of Pathology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
- 3Department of Neurosurgery, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, P.O. Box 320, Helsinki, FI- 00029, Finland.
Abstract
Meningiomas are the most frequently reported primary brain and other central nervous system tumors and account for more than one-third of all primary CNS tumors. High-grade meningiomas (WHO grades 2 and 3) are associated with significantly poorer prognosis and a higher risk of recurrence than grade 1 tumors, despite surgery and radiotherapy. Although several genetic and epigenetic alterations, including NF2 inactivation and related molecular drivers, have been identified in these tumors, effective systemic treatment options remain limited. Increasing evidence indicates that the Wnt/β-catenin signaling pathway is altered in meningiomas, as demonstrated by dysregulated expression of β-catenin, pathway regulators, and downstream transcriptional activity in different studies. Mechanistic studies in meningioma models show that Merlin S13 dephosphorylation, rather than Merlin loss alone, can attenuate inhibitory Merlin-β-catenin interactions, promote β-catenin-dependent Wnt signaling, and support tumor growth in NF2-wildtype meningiomas. Because the Wnt pathway regulates key processes such as proliferation, differentiation, apoptosis resistance, and tumor microenvironment interactions, its dysregulation may contribute to meningioma progression, particularly in biologically aggressive or higher-grade tumors. A better understanding of these mechanisms may help identify more rational therapeutic approaches for aggressive meningiomas. However, their clinical relevance will depend on whether candidate strategies can achieve adequate tumor exposure while maintaining acceptable systemic and CNS safety.
Related
- Editorial: Decoding cancer complexity with artificial intelligence and molecular level studies: informatics-driven approaches for therapeutic innovation
- From Molecular Pathogenesis to Therapeutic Innovations in Human Cytomegalovirus Research
- Ferroptosis and Cuproptosis in the Pathogenesis of Breast Cancer: Molecular Mechanisms, Crosstalk, and Therapeutic Perspectives
- Post-Translational Modification Crosstalk in Gastric Cancer: Molecular Switches, Signaling Networks, and Therapeutic Opportunities, with Comparative Insights from Colorectal Cancer
- NAD+ signaling in Parkinson's disease: molecular mechanisms and therapeutic perspectives
BibTeX
@article{kumar2026signaling,
title = {{The Wnt signaling networks in higher-grade meningiomas: from molecular pathogenesis to therapeutic innovation.}},
author = {Arathy S Kumar and Olli Tynninen and Miikka Korja},
journal = {Cancer cell international},
year = {2026},
month = jul,
doi = {10.1186/s12935-026-04393-1},
url = {https://europepmc.org/article/MED/42907832},
note = {CC BY},
}
RIS
TY - JOUR
TI - The Wnt signaling networks in higher-grade meningiomas: from molecular pathogenesis to therapeutic innovation.
AU - Arathy S Kumar
AU - Olli Tynninen
AU - Miikka Korja
PY - 2026
DA - 2026/07/01
JO - Cancer cell international
DO - 10.1186/s12935-026-04393-1
UR - https://europepmc.org/article/MED/42907832
AB - Meningiomas are the most frequently reported primary brain and other central nervous system tumors and account for more than one-third of all primary CNS tumors. High-grade meningiomas (WHO grades 2 and 3) are associated with significantly poorer prognosis and a higher risk of recurrence than grade 1 tumors, despite surgery and radiotherapy. Although several genetic and epigenetic alterations, including NF2 inactivation and related molecular drivers, have been identified in these tumors, effective systemic treatment options remain limited. Increasing evidence indicates that the Wnt/β-catenin signaling pathway is altered in meningiomas, as demonstrated by dysregulated expression of β-catenin, pathway regulators, and downstream transcriptional activity in different studies. Mechanistic studies in meningioma models show that Merlin S13 dephosphorylation, rather than Merlin loss alone, can attenuate inhibitory Merlin-β-catenin interactions, promote β-catenin-dependent Wnt signaling, and support tumor growth in NF2-wildtype meningiomas. Because the Wnt pathway regulates key processes such as proliferation, differentiation, apoptosis resistance, and tumor microenvironment interactions, its dysregulation may contribute to meningioma progression, particularly in biologically aggressive or higher-grade tumors. A better understanding of these mechanisms may help identify more rational therapeutic approaches for aggressive meningiomas. However, their clinical relevance will depend on whether candidate strategies can achieve adequate tumor exposure while maintaining acceptable systemic and CNS safety.
SN - 1475-2867
ER -